Reducing Biologics Manufacturing Cost
$200 billion global biologics market
mAbs account for almost half of the biologics market
Global biologic drugs market is valued at over $200 billion.
mAbs, or monoclonal antibodies, are the single most important part of the biologics market, accounting for almost half of the total market.
We are the exclusive licensee of various technologies that are expected to dramatically decrease mAb production costs by reducing capital equipment costs, production facility foot-print square footage, and operational expenditures.
Managing Neurological Conditions
In developed countries, stroke is the first leading cause for disability, second leading cause of dementia and third leading cause of death
Low and middle-income countries account for 85.5% of total stroke deaths worldwide
An embolic stroke occurs when the blood supply to the brain is blocked. This leads to a lack of oxygen, or hypoxia, in parts of the brain resulting in tissue death and without intervention the volume of tissue death increases quickly.
Our unique technology, and associated GOLD diagnostic imaging technology will provide a comprehensive solution to the diagnosis and treatment of acute ischaemic stroke. The diagnostic application provides a rapid assessment of tissue damage and viability in stroke patients. The oxygen carrying capabilities and small particle size (“nanoparticle”), delivers therapeutic benefit by protecting tissue at risk until normal blood flow can be restored.
Our technology could significantly improve patient outcomes, better-inform clinical interventions, and lengthen the therapeutic time window in this hugely under-served, seriously ill population of patients.
Managing Infectious Diseases
The current pandemic has further highlighted the enormity of infectious diseases. As COVID-19 rattles the world, there are new treatment options under development globally including better diagnostics, better vaccines and other treatment options.
Molecular and antigen tests are used to detect viral load for an active COVID-19 infection and antibody tests are used to detect presence of antibodies for an active or past COVID-19 infection.
Additionally, one of the key issues being analyzed is oxygenation of tissues, which we believe may unlock vast potential in treatment modalities.
Besides the very high costs of intensive care the numbers of ICU beds are also limited worldwide, especially in the developing world. Furthermore, to rapidly increase ICU beds to treat COVID-19 is difficult as it requires highly trained Physicians and Nurses to manage ventilators and other devices for ventilation. Any means of improving oxygenation by only using a face mask could reduce or mitigate the need for ICU beds. This could be transformational in the management of hypoxemic COVID-19 patients, especially in the developing world.
COVID-19 has infected around 85 million people worldwide
An unprecedented death toll of 2 million has shocked the world
We are developing a new technology to help carry oxygen that may be a solution to improving blood oxygenation using a face mask and thereby keeping the patient in the green zone managed in a medical bed and preventing progression into the ICU.
Managing Skin Care
Worldwide obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese.
We are the exclusive licensee of a platform technology to address issues related to chafing, a very common issue in people pursuing active physical activities such as sports, cycling, trekking, gym, swimming or if one is overweight or obese.
650 million obese people globally
Restoring Vaginal Health
According to the Third consensus meeting of Indian Menopause Society, in the next few years, India is expected to have over 100 million menopausal population. Average age of menopause is 47.5 years in Indian women with an average life expectancy of 71 years. While the varied lifestyles of people in the country, the rural urban divide (72% is rural), the economic imbalance between the poor, middle class, affluent and the multicultural, multiethnic, multireligious composition of the population makes it difficult to formulate generalized recommendations, we believe that many women suffer from VVA symptoms including dyspareunia (pain during sexual intercourse), vaginal dryness, and vaginal irritation.
We are the exclusive licensee of various technologies that strive to improve the quality of women’s health by addressing overlooked, unmet medical needs with novel treatment options that are inspired by the intrinsic biology and that provide an innovative solution to actually meet the medical need. We are licensing a unique bio-inspired platform technology designed to yield multiple pipeline products for the vaginal health markets. Our initial product comprises a non-hormonal, non-prescription formulation designed to work with the biochemistry to restore vaginal physiology and treat symptoms in post-menopausal women suffering from vulvovaginal atrophy (VVA).